SVB Leerink Continues to Strengthen Healthcare Equity Research Practice with Hire of David Risinger
SVB Leerink, an investment bank focused on the innovation economy, has announced the hiring of David Risinger as a Senior Managing Director in its healthcare equity research team.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
SVB Leerink, an investment bank focused on the innovation economy, has announced the hiring of David Risinger as a Senior Managing Director in its healthcare equity research team. Risinger, previously with Morgan Stanley, brings extensive experience in biopharmaceutical research. His appointment is expected to enhance SVB Leerink's capabilities in providing differentiated research to clients. Director of Research Jim Kelly emphasized Risinger's expertise as a significant asset for the firm's future growth in the healthcare sector.
Positive
- David Risinger's hiring strengthens SVB Leerink's healthcare equity research team.
- Risinger's extensive experience in biopharmaceuticals can elevate research offerings.
Negative
- None.
Details
News Market Reaction – SIVB
The recorded move for SIVB in the trading session of this news was -3.43%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Jan. 4, 2022 /PRNewswire/ -- SVB Leerink, a leading investment bank serving the innovation economy, announced today that David Risinger, CFA, has joined the firm's healthcare equity research team covering biopharmaceutical companies.
David joins SVB Leerink as a Senior Managing Director reporting to Director of Research, Jim Kelly. David's most recent Wall Street role was the Head of US Major and Specialty Pharmaceuticals Equity Research for Morgan Stanley & Co. Prior to that, David held roles at Merrill Lynch & Co. and Dillon, Read & Co.
"David is a strong addition to SVB Leerink, building upon our leadership across the healthcare industry," said Jim Kelly. "His wealth of expertise covering the biopharma industry and his depth of relationships will serve to elevate our offerings for our clients and partners."
Risinger stated: "I am excited to join SVB Leerink to continue to develop its offering in biopharma research. This is a tremendous opportunity to work with a talented team that has proven its leadership in healthcare equity research and its commitment to producing a deep and differentiated research product for its clients."
To learn more, visit: https://www.svbleerink.com/
About SVB Leerink
As a leading investment bank serving the innovation economy, SVB Leerink helps its clients move healthcare and technology forward. With differentiated sector knowledge, deep expertise, and an extensive suite of capital market and advisory solutions, the firm is the innovation economy's partner of choice. SVB Leerink is a wholly-owned subsidiary of SVB Financial Group and is a member of FINRA/SIPC. Learn more at svbleerink.com. [SIVB-L]
SVB Leerink
Contact: Diane Vieira
(617) 918-4097
Weber Shandwick
Contact: Patrick Lovett
(212) 546 7828
View original content to download multimedia:https://www.prnewswire.com/news-releases/svb-leerink-continues-to-strengthen-healthcare-equity-research-practice-with-hire-of-david-risinger-301453852.html
SOURCE SVB Leerink
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.